Past, Present, and Future of Targeting Ras for Cancer Therapies.

摘要: For decades, mutant Ras (mut-Ras) proteins have been identified as drivers of multiple cancers including pancreatic, lung, and colon cancers. However, targeting this oncogene has challenging no inhibitors are on the market to date. Lately several candidates downstream pathways signaling, PI3K Raf, were approved for cancer treatment. they do not present promising therapeutic effects patients harboring mutations. Recently, a variety compounds reported impair activity Ras, these exciting discoveries reignite hope development novel drugs mut-Ras. In article, we will review progress made in field current state-of-the-art technologies develop inhibitors. Also discuss future direction Ras.